Average phantom limb pain
| Group 1 | Group 2* | |||
| Average PLP (SD, N) | Average reduction from BL (SD) | Average PLP (SD, N) | Average reduction from BL (SD) | |
| Baseline | 6.9 (1.7, 11) | n/a | 6.8 (1.7, 13) | n/a |
| Week 4 | 3.6 (2.6, 11) | 3.3 (1.9) | 5.4 (2.3, 13) | 1.5 (1.4) |
| Week 8 (EOT) | 3.1 (2.8, 11) | 3.8 (2.2)† | 4.7 (2.4, 13) | 2.2 (1.7)† |
| Month 3 | 2.9 (2.8, 10) | 3.5 (2.3)† | 5.3 (2.6, 10) | 1.7 (2.4) |
| Month 12 | 3.8 (3.8, 8) | 2.6 (3.7) | 3.5 (2.6, 4) | 2.0 (2.2) |
*Group 2 crossed over at week 4 to receive 4 weeks of active stimulation.
†P<0.05 compared with group 2 at the end of the placebo period.
BL, baseline; EOT, end of treatment; n/a, not applicable; PLP, phantom limb pain.